The Effects of Different Long-acting Bronchodilator Medications on Asthma Patients With Different Genetic Variations
Summary
This study is looking at the effects of certain long-acting bronchodilators on patients with asthma who have specific genetic variations. The investigators are interested in a certain common genetic variation in the receptor for beta-agonists, which is found in as many of one-sixth of the population. There is evidence that patients with asthma who have this variation may not do as well when treated with albuterol on a regular basis. The investigators will be looking at whether patients with this variation have more asthma exacerbations over the course of a year when treated with salmeterol or formoterol, which are long-acting forms of albuterol; and whether these patients have fewer exacerbations when treated with tiotropium, which is a different long-acting bronchodilator that does not act at this receptor. In both groups patients will also be receiving inhaled steroids.
Timeline
- Start
- 2008-06
- Primary completion
- 2010-06
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Formoterol | Other / unclassified | 12 ug | Inhaled |
| Comparator | Salmeterol | Other / unclassified | 50 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 18 ug | Inhaled |
| Background | Budesonide | Small molecule | 90 ug | Inhaled |
| Background | Budesonide | Small molecule | 180 ug | Inhaled |
| Background | Fluticasone propionate | Other / unclassified | 44 ug | Inhaled |
| Background | Fluticasone propionate | Other / unclassified | 100 ug | Inhaled |
| Background | Fluticasone propionate | Other / unclassified | 110 ug | Inhaled |
| Background | Fluticasone propionate | Other / unclassified | 220 ug | Inhaled |